Afatinib in locally advanced/metastatic NSCLC harboring common mutations, after chemotherapy: a Phase IV study.

Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with mutation-positive (m+) non-small-cell lung cancer (NSCLC) following chemotherapy.

Patients & Methods: In this open-label, single-arm Phase IV study, patients with m+ (Del19/L858R) NSCLC who had progressed following platinum-based chemotherapy received afatinib (starting dose 40 mg/day). The primary end point was confirmed objective response.

A very rare presentation of lung cancer: Metastases to the distal phalanx of index-case report.

Rationale: Acrometastases of the hand are an unusual sign of lung cancer onset and may often be mistaken for other benign disorders, thus delaying diagnosis and treatment.

Patient Concerns: A 58-year-old man presented at the Rheumatology Clinic with a lump in the distal phalanx of the right index finger associated with intense pain, swelling, rib pain, and hemoptysis.

Diagnoses: Given the clinical manifestations, an x-ray of the right hand was performed, and it revealed an osteolytic lesion in the distal phalanx of the right index finger.

[Age-related prognostic factors and treatment results for advanced non-small cell lung cancer (NSCLC)].

Unlabelled: There is much debate whether the choice of management for elderly patients with locally advanced, inoperable NSCLC with good performance status (PS) should be made entirely on terms of age.

Material And Method: We compared the results of chemotherapy (CT), radiotherapy (RT) and chemoradiotherapy (CT-RT) of the elderly with those of younger patients, and studied predictive factors for survival in these age groups. 231 patients with advanced NSCLC were included in this study, being grouped by age: > 65 years (148p, 64.